DK1250155T3 - Modulatorer og inhibitorer af angiogenese og vaskulær permeabilitet - Google Patents

Modulatorer og inhibitorer af angiogenese og vaskulær permeabilitet

Info

Publication number
DK1250155T3
DK1250155T3 DK00990365T DK00990365T DK1250155T3 DK 1250155 T3 DK1250155 T3 DK 1250155T3 DK 00990365 T DK00990365 T DK 00990365T DK 00990365 T DK00990365 T DK 00990365T DK 1250155 T3 DK1250155 T3 DK 1250155T3
Authority
DK
Denmark
Prior art keywords
protein
src
modified
yes
inhibitors
Prior art date
Application number
DK00990365T
Other languages
English (en)
Inventor
Robert Paul
David A Cheresh
Brian Eliceiri
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/470,881 external-priority patent/US6685938B1/en
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Application granted granted Critical
Publication of DK1250155T3 publication Critical patent/DK1250155T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0271—Chimeric animals, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
DK00990365T 1999-12-22 2000-12-22 Modulatorer og inhibitorer af angiogenese og vaskulær permeabilitet DK1250155T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/470,881 US6685938B1 (en) 1998-05-29 1999-12-22 Methods and compositions useful for modulation of angiogenesis and vascular permeability using SRC or Yes tyrosine kinases
US53824800A 2000-03-29 2000-03-29
PCT/US2000/035396 WO2001045751A1 (en) 1999-12-22 2000-12-22 Angiogenesis and vascular permeability modulators and inhibitors

Publications (1)

Publication Number Publication Date
DK1250155T3 true DK1250155T3 (da) 2008-08-25

Family

ID=27043259

Family Applications (2)

Application Number Title Priority Date Filing Date
DK07020078.7T DK1905457T3 (da) 1999-12-22 2000-12-22 Farmaceutiske sammensætninger omfattende Src og/eller Yes samt anvendelse deraf
DK00990365T DK1250155T3 (da) 1999-12-22 2000-12-22 Modulatorer og inhibitorer af angiogenese og vaskulær permeabilitet

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK07020078.7T DK1905457T3 (da) 1999-12-22 2000-12-22 Farmaceutiske sammensætninger omfattende Src og/eller Yes samt anvendelse deraf

Country Status (19)

Country Link
EP (2) EP1250155B1 (da)
JP (1) JP2003518077A (da)
KR (1) KR100813818B1 (da)
CN (1) CN1434727A (da)
AT (2) ATE392215T1 (da)
AU (1) AU781444B2 (da)
BR (1) BR0016547A (da)
CA (1) CA2395136A1 (da)
CZ (1) CZ304320B6 (da)
DE (1) DE60038631T2 (da)
DK (2) DK1905457T3 (da)
ES (2) ES2383763T3 (da)
HU (1) HU229628B1 (da)
NO (1) NO20023036L (da)
PL (1) PL356815A1 (da)
PT (2) PT1905457E (da)
RU (1) RU2271216C2 (da)
SK (1) SK287575B6 (da)
WO (1) WO2001045751A1 (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030130209A1 (en) * 1999-12-22 2003-07-10 Cheresh David A. Method of treatment of myocardial infarction
US7115651B2 (en) 2000-08-25 2006-10-03 Sloan-Kettering Institute For Cancer Research Macrocycles and uses thereof
US20030207856A1 (en) * 2002-03-18 2003-11-06 Patrice Tremble Medical devices and compositions for delivering anti-proliferatives to anatomical sites at risk for restenosis
AU2003281152A1 (en) * 2002-07-12 2004-02-02 Yihai Cao A method for inhibiting vascular permeability and tissue edema
EP1413887A1 (en) * 2002-10-22 2004-04-28 Aventis Pharma S.A. Inhibitors of Src kinase for use in Alzheimer's disease
WO2004056386A2 (en) * 2002-12-19 2004-07-08 To-Bbb Holding B.V. Nucleic acids involved in blood-brain barrier control
GB0307333D0 (en) * 2003-03-29 2003-05-07 Astrazeneca Ab Therapeutic agent
DE602005023587D1 (de) * 2004-01-21 2010-10-28 Univ Emory Zusammensetzungen und verwendung von tyrosinkinase-hemmern zur behandlung von pathogenen infektionen
US20060094682A1 (en) 2004-10-29 2006-05-04 Odyssey Thera, Inc. Kinase inhibitors for the treatment of diabetes and obesity
JP2009521510A (ja) * 2005-12-23 2009-06-04 アルコン，インコーポレイテッド 眼への受容体チロシンキナーゼ阻害（ｒｔｋｉ）化合物の送達のための医薬製剤
JP5698905B2 (ja) * 2006-05-22 2015-04-08 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 一酸化窒素の送達のための方法
DK1862802T3 (da) * 2006-06-01 2009-04-14 Cellzome Ag Fremgangsmåde til identifikation af med ZAP-70 vekselvirkende molekyler og til rensning af ZAP-70
DE102007037008B4 (de) * 2007-08-06 2015-09-10 Siemens Aktiengesellschaft Diagnosesubstanz zur Anwendung in einem Verfahren zur Bestimmung der Aggressivität eines Prostatatumors
US8889840B2 (en) * 2009-10-29 2014-11-18 Industry-Academic Cooperation Foundation, Yonsei University Vascular leakage inhibitor
US8557513B2 (en) * 2011-06-27 2013-10-15 Biocrine Ab Methods for treating and/or limiting development of diabetes
US10293023B2 (en) 2013-03-15 2019-05-21 Children's Medical Center Corporation Method of altering vascular permeability and uses thereof
CN105288654B (zh) * 2015-01-23 2018-11-30 中国人民解放军第二军医大学 蛋白酪氨酸激酶fyn癌基因在防治肠道病毒71型感染中的应用
CN105311645B (zh) * 2015-01-23 2018-11-30 中国人民解放军第二军医大学 胚胎fyn相关底物efs在防治肠道病毒71型感染中的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356167A (en) 1978-01-27 1982-10-26 Sandoz, Inc. Liposome drug delivery systems
US5092885A (en) 1987-02-12 1992-03-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Peptides with laminin activity
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
US5542935A (en) 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5580575A (en) 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5192744A (en) 1990-01-12 1993-03-09 Northwestern University Method of inhibiting angiogenesis of tumors
ATE120860T1 (de) * 1990-01-26 1995-04-15 Washington Res Found Immunreaktivität gegenüber exprimierten aktivierten oncogenen zur diagnose und behandlung von bösartigen geschwülsten.
DE69114782T2 (de) 1990-08-08 1996-04-18 Takeda Chemical Industries Ltd Intravaskulär embolisierendes Mittel mit Gehalt an einem die Angiogenesis hemmenden Stoff.
US5753230A (en) 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
US5643599A (en) 1995-06-07 1997-07-01 President And Fellows Of Harvard College Intracellular delivery of macromolecules
US5922697A (en) * 1996-10-02 1999-07-13 Warner-Lambert Company Compounds, compositions and methods for inhibiting the binding of proteins containing an SH2 domain to cognate phosphorylated proteins
US6093740A (en) * 1997-04-30 2000-07-25 Eli Lilly And Company Therapeutic treatment for skin disorders
ATE292623T1 (de) * 1997-05-07 2005-04-15 Sugen Inc 2-indolinonderivate als modulatoren der proteinkinase-ativität
US6723694B1 (en) * 1997-05-21 2004-04-20 The Children's Medical Center Corp. Short peptides which selectively modulate intracellular signalling
US6420338B1 (en) * 1997-06-13 2002-07-16 New York University Medical Center Inhibition of the Src kinase family pathway as a method of treating HBV infection and hepatocellular carcinoma
WO1999017770A1 (en) * 1997-10-06 1999-04-15 Basf Aktiengesellschaft Indeno[1,2-c]pyrazole derivatives for inhibiting tyrosine kinase activity
ES2361659T3 (es) * 1998-05-29 2011-06-21 The Scripps Research Institute PROCEDIMIENTOS ÚTILES PARA LA MODULACIÓN DE LA ANGIOGÉNESIS QUE UTILIZAN LA TIROSINA CINASA Src.
BR9915139A (pt) * 1998-11-06 2001-08-07 Basf Ag Método de inibir a hiperpermeabilidade vascular, e de inibir um processo ou estado fisiológico em um indivìduo

Also Published As

Publication number Publication date
SK8492002A3 (en) 2002-11-06
EP1905457B1 (en) 2012-04-18
BR0016547A (pt) 2002-10-29
RU2271216C2 (ru) 2006-03-10
KR100813818B1 (ko) 2008-03-17
PT1905457E (pt) 2012-05-25
KR20020063259A (ko) 2002-08-01
EP1250155A4 (en) 2003-08-20
NO20023036D0 (no) 2002-06-21
NO20023036L (no) 2002-07-22
CN1434727A (zh) 2003-08-06
EP1250155B1 (en) 2008-04-16
HUP0203957A3 (en) 2005-07-28
WO2001045751A1 (en) 2001-06-28
CA2395136A1 (en) 2001-06-28
HUP0203957A2 (hu) 2003-03-28
ATE553782T1 (de) 2012-05-15
HU229628B1 (en) 2014-03-28
SK287575B6 (sk) 2011-03-04
PT1250155E (pt) 2008-06-06
EP1250155A1 (en) 2002-10-23
AU781444B2 (en) 2005-05-26
CZ304320B6 (cs) 2014-03-05
DK1905457T3 (da) 2012-05-29
AU2740001A (en) 2001-07-03
EP1905457A1 (en) 2008-04-02
ES2303514T3 (es) 2008-08-16
DE60038631D1 (de) 2008-05-29
JP2003518077A (ja) 2003-06-03
DE60038631T2 (de) 2009-06-10
RU2002119399A (ru) 2004-02-27
ATE392215T1 (de) 2008-05-15
ES2383763T3 (es) 2012-06-26
PL356815A1 (en) 2004-07-12

Similar Documents

Publication Publication Date Title
DK1250155T3 (da) Modulatorer og inhibitorer af angiogenese og vaskulær permeabilitet
HUS1700003I1 (hu) Pirimidinamin-származékok és ezeket tartalmazó gyógyászati készítmények, mint angiogenézis modulátorok
ATE469888T1 (de) Indazol-, benzisoxazol- und benzisothiazol- kinaseinhibitoren
ATE556059T1 (de) Pyrazolderivate zur behandlung von hiv
WO2002057259A3 (en) Pyrazole compounds useful as protein kinase inhibitors
DE60105295D1 (de) Chinazolinderivate zur behandlung von tumoren
CY1108041T1 (el) Αναστολεις της rho-κινασης
DE60120494D1 (de) Substituieten triazoldiamin derivaten und ihre verwendung als kinase inhibitoren
DE50213524D1 (de) Kationische sterolderivate, ph-sensitive liposomen diese umfassend und verfahren zur wirkstoffbeladung von liposomen
BR0215360A (pt) Derivados de indolina úteis como inibidores de proteìna quinase
WO2002085906A3 (en) Phthalazinones derivatives useful as pde4/7 inhibitors
ATE260274T1 (de) Furanonderivate als inhibitoren von cathepsin s
BRPI0407841A (pt) inibidores heterocìclicos de quinase
ATE302002T1 (de) Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit
NO20006026L (no) Fremgangsmåter og blandinger for modulering av angiogenese ved bruk av tyrosin kinase SRC
DE60311284D1 (de) 4-(3,5-dicyanophenoxy)pyrazol-derivate zur verwendung als reverse transkriptase modulatoren zur behandlung von u.a. hiv
ATE314070T1 (de) Verwendung von pyridoindolonderivaten zur herstellung von antikrebsmitteln
DE50105650D1 (de) Verwendung von niedermolekularen heparin zur behandlung von osteoarthrose
DE60215947D1 (de) Pyridin-2-yl-methylamin-derivate zur behandlung von opiatsucht